Skip to main content

CORRECTION article

Front. Oncol., 31 October 2022
Sec. Molecular and Cellular Oncology
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1063651

Corrigendum: Cross-resistance among sequential cancer therapeutics: An emerging issue

This article is a correction to:

  1. Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue

    1. Read original article
Rossella LoriaRossella Loria1Patrizia ViciPatrizia Vici2Francesca Sofia Di Lisa,Francesca Sofia Di Lisa2,3Silvia SodduSilvia Soddu1Marcello Maugeri-SaccMarcello Maugeri-Saccà4Giulia Bon*Giulia Bon1*
  • 1Cellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy
  • 2Unit of Phase IV Trials, IRCCS Regina Elena National Cancer Institute, Rome, Italy
  • 3Medical Oncology A, Department of Radiological, Oncological, and Anatomo-Pathological Sciences, Umberto I University Hospital, University Sapienza, Rome, Italy
  • 4Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy

A Corrigendum on
Cross-resistance among sequential cancer therapeutics: An emerging issue

By Loria R, Vici P, Di Lisa FS, Soddu S, Maugeri-Saccà M, Bon G. (2022) 12:877380. doi: 10.3389/fonc.2022.877380

In the published article, there was an error in affiliations 1, 2, and 4. In these affiliations, “Istituto di Ricerca e Cura a Carattere Scientifico Regina Elena National Cancer Institute, Rome, Italy” has been changed to “IRCCS Regina Elena National Cancer Institute, Rome, Italy”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: targeted-therapy, cancer therapeutics resistance, cross-resistance, sequential therapeutics, personalized oncology

Citation: Loria R, Vici P, Di Lisa FS, Soddu S, Maugeri-Saccà M and Bon G (2022) Corrigendum: Cross-resistance among sequential cancer therapeutics: An emerging issue. Front. Oncol. 12:1063651. doi: 10.3389/fonc.2022.1063651

Received: 07 October 2022; Accepted: 21 October 2022;
Published: 31 October 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Loria, Vici, Di Lisa, Soddu, Maugeri-Saccà and Bon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Giulia Bon, Z2l1bGlhLmJvbkBpZm8uaXQ=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.